Assessment of local adverse reactions to subcutaneous immunoglobulin (SCIG) in clinical trials
In their recent paper on the North American pivotal trial of a new 20% immunoglobulin (Ig) for subcutaneous (SC) use, Suez et al. report an incidence of local adverse events (AE) of 0.015 events/infusion and compared this to rates reported in other studies of different products. Comparison of differ...
Main Authors: | Ballow, M, Wasserman, R, Jolles, S, Chapel, H, Berger, M, Misbah, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer
2017
|
Similar Items
-
Local adverse reaction rates decreased over time during treatment with recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (fSCIG) in patients with primary immunodeficiency diseases in the fSCIG phase 3 studies
by: Lina Laguado, et al.
Published: (2018-06-01) -
Subcutaneous Immunoglobulin (SCig) for Maintenance Therapy in Severe POTS: A Case Report.
by: Tahrima Ferdous
Published: (2023-12-01) -
CANO-ACIO CLINICAL LECTURESHIP The development and implementation of a subcutaneous immunoglobulin (SCIG) program at CancerCare Manitoba
by: Erin Streu
Published: (2016-04-01) -
Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese
by: Andy Ka Chun Kan, et al.
Published: (2022-12-01) -
Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)